Aveo Oncology Inc., of Cambridge, Mass., and Eusa Pharma Inc., of Hemel Hempstead, U.K., reported preliminary results of the phase II portion of the TiNivo phase Ib/II trial testing Fotivda (tivozanib), a vascular endothelial growth factor tyrosine kinase inhibitor, in combination with PD-1 inhibitor Opdivo (nivolumab, Bristol-Myers Squibb Co.) in patients with metastatic renal cell carcinoma at the 2018 American Society of Clinical Oncology's Genitourinary Cancers Symposium.